HIV genotype mutations evoked by nelfinavir-based regimens: frequency, background, and consequences on subsequent treatment options

J Acquir Immune Defic Syndr. 2002 Jun 1;30(2):258-60. doi: 10.1097/00042560-200206010-00016.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Anti-HIV Agents / therapeutic use
  • Drug Resistance, Viral / genetics*
  • Drug Therapy, Combination
  • Genotype
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • HIV Protease / genetics*
  • HIV Protease Inhibitors / pharmacology*
  • HIV Protease Inhibitors / therapeutic use
  • HIV-1 / enzymology*
  • HIV-1 / genetics
  • Humans
  • Mutation*
  • Nelfinavir / pharmacology*
  • Nelfinavir / therapeutic use
  • Reverse Transcriptase Inhibitors / therapeutic use

Substances

  • Anti-HIV Agents
  • HIV Protease Inhibitors
  • Reverse Transcriptase Inhibitors
  • HIV Protease
  • Nelfinavir